Adrenocortical carcinoma: A single institution experience

American Surgeon

Volumn 71, Issue 1, 2005, Pages 90-94

  Gomez Rivera, Fernando ^a   Medina Franco, Heriberto ^b   Arch Ferrer, Jorge E ^a   Heslin, Martin J ^a  

^a University of Alabama at Birmingham   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MEDICAL RECORD; METASTASIS; POSTOPERATIVE COMPLICATION; PROGNOSIS; SURGICAL MORTALITY; ADRENAL CORTEX TUMOR; ANGIOGRAPHY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 14944351344     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: 10.1177/000313480507100118     Document Type: Article

References (25)

1. Ng L, Libertine JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003;169:5-11.
2. McDougal WS. Adrenal cortical cancer. In: Scott HW Jr., ed. Surgery of the Adrenal Glands. Philadelphia: Lippincott, 1996, pp 241-50.
3. Norton JA. Adrenal tumors. In: DeVita HSRS, ed. Cancer: Principles and Practic of Oncology. Philadelphia: Lippincott-Raven, 1997, p 1659.
4. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978;120:660-5.
5. MacFarlane DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958;23:155-86.
6. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001;25:891-7.
7. Woolen MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55.
8. Chow WH, Hsing AW, McLaughlin JK, Fraumeni JF Jr. Smoking and adrenal cancer mortality among United States veterans. Cancer Epidemiol Biomarkers Prev 1996;5:79-80.
9. Hsing AW, Nam JM, Co Chien HT, et al. Risk factors for adrenal cancer: an exploratory study. Int J Cancer 1996;65:432-6.
10. Proye CA. Adrenocortical carcinoma: nonfunctioning and functioning. In: Clark O, Duh QY, eds. Textbook of Endocrine Surgery. W.B. Saunders, 1997, pp 490-6.
11. Siren JE, Haapiainen RK, Huikuri KT, Sivula AH. Incidentalomas of the adrenal gland: 36 operated patients and review of literature. World J Surg 1993;17:634-9.
12. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg 1997;132:914-9.
13. Ross NS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990;323: 1401-5.
14. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-26.
15. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6.
16. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963-70.
17. Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982;117:1142-6.
18. Schteingart DE. Current perspective in the diagnosis and treatment of adrenocortical carcinoma. Rev Endocr Metab Disord 2001;2:323-33.
19. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-23.
20. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92:1113-21.
21. Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer 1989;64:765-9.
22. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-43.
23. Ahlman H, Khorram-Manesh A, Jansson S, et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001;25: 927-33.
24. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83:2194-200.
25. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-26.